Shire to present chronic hypoparathyroidism data at ENDO 2018

Shire has announced that it will be sharing its latest chronic hypoparathyroidism research insights at this year's annual meeting and exposition of the Endocrine Society (ENDO).

The conference, running from March 17th to 20th in Chicago, will see Shire presenting new data on recombinant human parathyroid hormone therapy and on the management of chronic hypoparathyroidism, a rare disease that can have a significant impact on patients.

Both clinical and real-world insights will be shared, including findings on how the disease affects renal parameters, its impact on health-related quality-of-life scores, and an analysis of the latest five-year results from the ongoing RACE study.

Dr Howard Mayer, senior vice-president and chief medical officer at Shire, said: "With our continuing programme of clinical and real-world insights on the chronic form of this rare endocrine disease, we are committed to expand the understanding of the long-term burden of the disease for patients."

Hypoparathyroidism occurs when inadequate levels of parathyroid hormone are secreted by the parathyroid glands, resulting in a mineral imbalance in the body. It can lead to both physical and cognitive symptoms.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.